After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Recently, Yahoo Finance discussed the stock, revealing that bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
BLUE belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.41 and fluctuated between $1.4300 as its day high and $1.3750 as its day low. The current market capitalization of Bluebird bio Inc is $271.76M. A total of 7.47 million shares were traded on the day, compared to an average of 11.03M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, BLUE has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 3,150 shares. Over the last 12 months, there were 11 BUYs and 8 SELLs from insiders. Insiders purchased 297,003 shares during that period but sold 29,964.
In the most recent transaction, Obenshain Andrew sold 3,162 shares of BLUE for 1.43 per share on Jan 05. After the transaction, the President and CEO now owns 287,972 company shares. In a previous transaction on Jan 05, Colvin Richard A sold 597 shares at 1.42 per share. BLUE shares that Chief Medical Officer owns now total 125,138.
Among the insiders who sold shares, Krawtschuk Christopher disposed of 4,526 shares on Dec 06 at a per-share price of $4.52. This resulted in the Chief Financial Officer holding 45,474 shares of BLUE after the transaction. In another insider transaction, Obenshain Andrew sold 807 shares at $3.17 per share on Nov 03. Company shares held by the President and CEO now total 291,134.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for BLUE in the last 3 months, the mean price target is $5.44 with high estimates of $13.00 and low estimates of $2.00. In terms of 52-week highs and lows, BLUE has a high of $7.78 and a low of $1.26.
As of this writing, BLUE has an earnings estimate of -$0.65 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.37 per share and a lower estimate of -$0.75. The company reported an EPS of -$0.67 in the last quarter, which was 6.90% higher than expectations of -$0.72.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BLUE’s latest balance sheet shows that the firm has $299.50M in Cash & Short Term Investments as of fiscal 2021. There were $89.58M in debt and $152.99M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $374.28M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BLUE is Buy with a score of 3.50.
